Wegovy vs Ozempic in the Philippines: same molecule, different bill

The one-line answer to "wegovy vs ozempic price philippines": same molecule, and Wegovy costs more at the matched 1 mg strength, by about 7 percent at Watsons. Every peso figure below was read from the seller's own listing and checked on 23 September 2026.

Novo Nordisk sells semaglutide under two injectable brands: Ozempic, which US FDA and EMA records list for type 2 diabetes, and Wegovy, which they list for weight management. The molecule in the pen is identical. What the branding changes is the labelled indication, the pen strengths on offer and, in the Philippines, the price.

The strength difference is the substantive one. Ozempic is listed here as 0.25 mg, 0.5 mg and 1 mg pens, and the FDA Philippines register holds no Ozempic 2 mg row. Wegovy is listed as 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg pens. In STEP 1, a 68-week phase 3 trial of 1,961 adults with obesity or overweight and no diabetes, body weight fell 14.9% on semaglutide 2.4 mg, the Wegovy strength, against 2.4% on placebo. At that strength, in STEP 3, a 68-week phase 3 trial of semaglutide 2.4 mg, nausea was reported by 58.2% of participants, against 22.1% on placebo.

Whether the higher strength is appropriate is a clinical question for a prescriber; this filing reports what each pen costs. A research-grade semaglutide vial is not a registered medicine and not a substitute for either prescribed pen.

All figures were checked on 23 September 2026. Watsons lists the Wegovy 0.25 mg, 0.5 mg and 1 mg pens at one price, ₱9,900, so the price steps up only at 1.7 mg and 2.4 mg. The complete pen-by-pen picture lives in the Ozempic price filing and the Wegovy price filing.

Ozempic is listed online by MedsGo, MedsGo on Lazada, Rose Pharmacy, Southstar Drug and Watsons, and Wegovy by MedsGo, MedsGo on Lazada, PULSE Clinic, Rose Pharmacy, Southstar Drug and Watsons, checked 23 September 2026. Widely listed is not the same as available: Manila Bulletin reported on 13 June 2026 that pharmacies had imposed allocation limits, commonly two pens per dosage per month, with pharmacists screening customers to protect diabetic supply.

A published listing is a price rather than a promise of stock. Mercury Drug publishes no prices online. Both brands require a prescription at every legitimate counter, and Watsons marks both as prescription required on its listings. The prescribing decision, on either pen, belongs with a licensed Philippine physician; the law is in the regulation hub.